Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Pharmacother ; 51(4): 286-292, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28228057

ABSTRACT

BACKGROUND: In cases of loop diuretic resistance in the intensive care unit (ICU), recommendations for a specific second-line thiazide agent are lacking. OBJECTIVE: To compare the effects of intravenous chlorothiazide (CTZ) and enteral metolazone (MET) on urine output (UOP) when added to furosemide monotherapy therapy in critically ill adults. METHODS: This was a retrospective cohort study conducted in the medical, surgical, and cardiothoracic ICUs of a quaternary medical center. The primary outcome was change in UOP induced by the study interventions compared with furosemide alone. Secondary outcomes included onset of diuresis, eventual need for hemodialysis, and incidence of adverse events. RESULTS: A total of 122 patients (58 in CTZ, 64 in MET) were included. When added to furosemide monotherapy, CTZ induced a greater change in UOP at 24 hours compared with MET (2405 vs 1646 mL, respectively; P = 0.01). CTZ also caused a more rapid dieresis: 1463 mL total UOP in the first 6 hours compared with 796 mL in the MET group ( P < 0.01). There were no differences found regarding ICU length of stay, need for renal replacement therapy, or survival to discharge. The CTZ arm required more potassium supplementation to maintain normokalemia (median 100 vs 57 mEq in MET; P = 0.02) and carried a higher cost (mean $97 vs $8, P < 0.01). CONCLUSION: Both CTZ and MET induced significant increases in UOP. CTZ induced a greater and more rapid change and was associated with higher cost and greater need for potassium replacement. Randomized controlled trials are needed to establish whether a preferable thiazide diuretic exists in this setting.


Subject(s)
Chlorothiazide/therapeutic use , Diuresis/drug effects , Intensive Care Units , Metolazone/therapeutic use , Sodium Potassium Chloride Symporter Inhibitors/therapeutic use , Administration, Intravenous , Administration, Oral , Adult , Chlorothiazide/administration & dosage , Chlorothiazide/adverse effects , Critical Illness , Drug Therapy, Combination , Female , Furosemide/administration & dosage , Furosemide/adverse effects , Furosemide/therapeutic use , Humans , Male , Metolazone/administration & dosage , Metolazone/adverse effects , Retrospective Studies , Sodium Potassium Chloride Symporter Inhibitors/administration & dosage , Sodium Potassium Chloride Symporter Inhibitors/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...